In this study, we used zinc finger nuclease-mediated knockout of the aryl hydrocarbon receptor (AHR) or AHR nuclear translocator (ARNT) in MCF7 and AHR knockout in MDA-MB-231 human breast cancer cells to investigate cross talk among AHR, ARNT, and estrogen receptor α (ERα). Knockout of AHR or ARNT prevented the 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-dependent induction of all AHR target genes examined. Knockout of AHR or ARNT also significantly reduced basal cytochrome P4501B1 (CYP1B1) expression levels, which were restored with overexpression of either protein but not with a DNA binding-deficient AHR mutant. Basal and TCDD-, 17β-estradiol (E2)-, or TCDD + E2-dependent recruitment of AHR, ARNT, ERα, NCoA3, and RNA polymerase II to CYP1B1 as well as CYP1B1 mRNA levels were abolished in MCF7-AHR ko and MDA-MB-231 AHR ko cells. However, reduced but significant E2-dependent recruitment of ERα, NCoA3, and RNA polymerase II to CYP1B1 and weak increases in CYP1B1 mRNA levels were observed in MCF7 ARNT ko cells. Interestingly, E2-dependent increases in trefoil factor 1, but not growth regulation by estrogen in breast cancer 1 (GREB1) mRNA levels, were dependent on ARNT expression. Moreover, the TCDD-dependent increases in the proteolytic degradation of ERα were prevented by the loss of AHR or ARNT. Our data show that AHR and ARNT play critical roles in the basal, TCDD, and E2-induced regulation of CYP1B1 but also reveal distinct roles for both proteins in ERα transactivation.
The aryl hydrocarbon receptor (AHR) is a transcription factor that was originally discovered because of its high affinity for the environmental contaminant 2,3,7,8-tetrachlorodibenzop-dioxin (TCDD) (Poland et al., 1976) . It is now known that several structurally diverse compounds bind to AHR, including halogenated aromatic hydrocarbons, carcinogenic polycyclic aromatic hydrocarbons (PAHs), phytochemicals, such as indoles, and endogenous compounds, including bilirubin, indigoids, and tryptophan derivatives (Denison and Nagy, 2003) .
AHR has been intensely studied due to its ligand-dependent upregulation of the cytochrome P450 (CYP) and other phase I and phase II drug-metabolizing enzymes (Hankinson, 1995) . Once activated by ligand, AHR translocates from the cytoplasm into the nucleus where it associates with its obligatory dimerization partner the AHR nuclear translocator (ARNT). The AHR/ARNT heterodimer recognizes a DNA sequence termed the AHR response element (AHRE; TnGCGTG) located within the regulatory regions of AHR target genes, such as CYP1A1 and CYP1B1. CYP1B1 is expressed in normal tissues, but it is more highly expressed in hormone-dependent cancers including prostate and breast cancers (Cavalieri et al., 2000; Tokizane et al., 2005) . CYP1B1 metabolically activates a variety of procarcinogens and promutagens and also catalyzes the 4-hydroxylation of 17β-estradiol (E2) in human breast tissue and mammary tumors (Cavalieri et al., 2000) . The metabolic conversion of estrogens to 4-hydroxy estrogens and their further oxidation to reactive quinones is thought to increase DNA damage and breast cancer risk (Cavalieri et al., 2000) . In addition to its regulation by AHR, CYP1B1 is regulated by other transcription factors and signaling molecules, including estrogen receptor α (ERα) and cyclic adenosine monophosphate (cAMP) (Tsuchiya et al., 2004; Zheng and Jefcoate, 2005) .
Cross talk between AHR and ERα is well documented and occurs through several different mechanisms; however, the precise molecular details remain elusive (Matthews et al., 2006; Wormke et al., 2003) . Activated AHR inhibits breast cancer cell growth, invasiveness, and colony formation (Hall et al., 2010; Zhang et al., 2009) . AHR also inhibits ERα-dependent signaling, by potentially lowering E2 levels, by altering the genomic binding patterns of ERα, and by reducing ERα protein levels via the 26S proteasome complex (Matthews et al., 2006 ; Wormke toxicological sciences 138(1), 89-103 2014 doi:10.1093/toxsci/kft274 Advance Access publication December 3, 2013 December 3, et al., 2003 . ARNT has been reported to act as an ERα coactivator, and competition for ARNT has been proposed as a potential mechanism of cross talk between AHR and ERα. More recently, ERα was found to inhibit TCDD-induced CYP1A1, but not CYP1B1 expression, by recruiting corepressors and increasing DNA methylation at this locus (Marques et al., 2013) . The effects of ERα and E2 on AHR transactivation are controversial and are influenced by cell context and ligand concentration (Beischlag and Perdew, 2005; Matthews et al., 2005; Thomsen et al., 1994) . Moreover, there are some reports that select AHR ligands exhibit estrogenic activity that is influenced by promoter and cell context (Boverhof et al., 2006) .
RNAi-mediated knockdown of AHR has provided new insights into the mechanism of AHR action and have helped dissect the mechanisms of cross talk between AHR and ERα . Despite the overall effectiveness of RNAi, this method does not eliminate AHR protein levels and the remaining protein may still elicit cellular responses. Other researchers have developed human breast cancer and mouse hepatoma cell lines deficient in AHR activity (MCF7 AH R100 and Hepa1 c4, c12, and c19) by long-term exposure to low levels of the genotoxic PAH, benzo [a] pyrene (Ciolino et al., 2002; Hankinson, 1983) . Although these cell lines have been important in understanding AHR action, a recent study revealed that the basal gene expression patterns among the Hepa1 variants were significantly different, suggesting that genes other than AHR or ARNT are differentially modified compared with wild-type (WT) cells (Fong et al., 2005) . New technologies such as zinc finger nucleases (ZFNs), transcriptional activator-like effector nucleases (TALENs), and the newly described clustered regularly interspaced short palindromic repeats (CRISPRs) offer the advantage of targeted gene deletion in cultured cell lines and nonmurine animal models (Cong et al., 2013; DeFrancesco, 2011; Porteus and Carroll, 2005) . These nucleases create sitespecific double-strand DNA breaks, which due to error prone DNA repair lead to insertions or deletions (termed indels) causing out-of-frame mutations (Porteus and Carroll, 2005) .
In this study, we used ZFN-targeted knockout of AHR or ARNT in ERα-positive (MCF7) and AHR knockout in ERα-negative (MDA-MB-231) breast cancer cells to dissect AHR signaling and cross talk between AHR and ERα. Our findings show that AHR and ARNT play critical roles in the basal, TCDD, and E2-induced regulation of CYP1B1. Our data also reveal that AHR and ARNT are required for the TCDD-dependent proteolytic degradation of ERα, but AHR and ARNT exhibit distinct roles in ERα transactivation. The cell line models described here are useful models to further delineate AHR mechanism of action and its cross talk with other signaling pathways.
MATERIAls AND METHODs
Chemicals. Antibodies used for chromatin immunoprecipitation (ChIP) experiments include: ERα, HC-20; AHR, H-211; ARNT, H-172; NCoA3, M-397 (Santa Cruz Biotechnology, Santa Cruz, California) and RNA polymerase II 8WG16 (Covance, Princeton, New Jersey). Primary antibodies used for Western blotting were: ERα, HC-20; AHR, H-211; ARNT, C-19; CYP1B1, H-105 (Santa Cruz Biotechnology). TCDD was purchased from Accustandard (New Haven, Connecticut), and dimethyl sulfoxide (DMSO) was purchased from Sigma (St Louis, Missouri). Cell culture media, fetal bovine serum (FBS), and trypsin were all purchased from Wisent Biosciences (Montreal, Quebec). All other chemicals and biochemicals were of the highest quality available from commercial vendors.
Generation of zinc finger-mediated AHR
ko and ARNT ko cell lines. MCF7 and MDA-MB-231 AHR ko cells were generated using validated CompoZr knockout ZFN plasmids targeting AHR (CKOZFND26436), and MCF7 ARNT ko cells were generated using validated ZFN plasmids targeting ARNT (CKOZFND3521) purchased from Sigma-Aldrich. Briefly, 2 × 10 6 MCF7 or 1 × 10 6 MDA-MB-231 cells were transfected with 2 μg of each ZFN plasmid targeting AHR or ARNT using nucleofector kit V and Amaxa nucleofector (Lonza, Mapleton, Illinois) according to the manufacturer's recommendations. Three days posttransfection, cells were serial diluted into 2 × 96-well plates from an initial seeding density of 100 000 cells/well. At least 24 clones generated from polyclonal cell populations that were screened for the presence of indels at the ZFN recognition site in exon 1 of AHR or exon 14 of ARNT by DNA sequencing. The ability of TCDD to induce CYP1A1 mRNA levels using qPCR was assessed in cell clones containing genetic alterations that resulted in out-of-frame mutations and improper translation of AHR or ARNT. MCF7, MCF7 AHR ko , and MCF7 ARNT ko cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% (vol/vol) FBS and 1% penicillin/streptomycin (PEST). MDA-MB-231 and MDA-MB-231 AHR ko cells were cultured in DMEM supplemented with 10% FBS, 1% PEST, and 1% nonessential amino acids. All cells were maintained at 37°C and 5% CO 2 and subcultured every 2-3 days.
RNAi-mediated knockdown of CYP1B1 and AHR. siCYP1B1 seq1 (SASI_Hs01_00020014), seq2 (SASI_Hs01_00301876), seq3 (SASI_ Hs01_00020012), and a universal negative control were from Sigma-Aldrich. MCF7 or MDA-MB-231 cells were seeded in a 6-well plate in medium containing 5% dextran-coated charcoal (DCC)-stripped FBS. After 24 h, 50nM of pooled siCYP1B1 or universal negative control were transfected using DharmaFECT1 (Dharmacon) according to manufacturer's instructions. For AHR knockdown, SMARTpool siAHR (L-004990-00-0020) (Dharmacon) was transfected into MCF7 cells as previously described (Ahmed et al., 2009 (Jiang and Jordan, 1992) , were seeded in 10-cm dishes using DMEM phenol red-free medium supplemented with 5% (vol/vol) DCC-FBS. After 72 h, cells were treated with DMSO (final concentration 0.1%), 10nM TCDD, 10nM E2, or 10nM E2 + 10nM TCDD for 45 min. ChIP assays were performed as previously described (Matthews et al., 2007) . Enrichment levels (relative to 100% total input) were determined by qPCR. The qPCR primers used in this study have been described elsewhere (Ahmed et al., 2009; Macpherson and Matthews, 2010) , except for the trefoil factor 1 (TFF-1) region: 5′CCGGCCATCTCT CACTATGAA-3′ and 5′-CCTCCCGCCAGGGTA AATAC-3′.
RNA isolation and qPCR. MCF7 or MDA-MB-231 cells were seeded in 6-well plates and grown in DMEM phenol red-free media supplemented with 5% DCC-FBS. After 72 h, cells were treated with DMSO, 10nM TCDD, 10nM E2, or 10nM E2 + 10nM TCDD for 6 h or 100μM of CoCl 2 for 24 h. RNA was isolated using the Aurum total RNA kit (Bio-Rad, Hercules, California) and reverse transcribed as previously described (Ahmed et al., 2009) . All target gene transcripts were normalized to ribosomal 18s RNA, and fold inductions were calculated using DMSO control samples and the comparative C T (ΔΔC T ) method. qPCR primers used in the study have been described elsewhere (Ahmed et al., 2009 ) with exception of the following primers: VEGF (vascular endothelial growth factor) 5′-TCCTCACACC ATTGAAACCA-3′ and 5′-GA TCCTGCCCTGTCTCTCTG-3′; CA9 (carbonic anhydrase IX) ZFN-Mediated KNocKout oF AHR or ARNT 5′-ACTTCAGCCGCTA CTTCCAA-3′ and 5′-AGAGGGTGTGGAGCTGCT TA-3′; SNX13 (sorting nexin-13) 5′-GAAGATTGACGGGTGCCAA T-3′ and 5′-TCC CTCAAGGAAAACTGGATAACT-3′; AGR3 (anterior gradient protein 3) 5′-GCCATTGC AATAAAAAAGGAAAA-3′ and 5′-GTCATCTCCCCA TCCTCT TGAG-3′; SETDB1 (SET domain, bifurcated 1) 5′-TGATGCTGG GAGCAGAA CTC-3′ and 5′-T TCTTAAGGCAGCCATAGCTTCA-3′; CTSK (cathepsin K) 5′-GGTTCCTGTTGGGC TTTTAGC-3′ and 5′-TTTGCCAGTT TTCTTCTTGAG TTG-3′; and TFF-1 5′-CATCG ACGTCCCTCCAGAAG AG-3′ and 5′-CTCT GGGACTAATCACCGTGCTG-3′.
Western blot. Proteins were resolved by SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes. The membranes were blocked in 2% (wt/vol) ECL-Advance blocking agent (GE Healthcare) for 1 h and then incubated with anti-ERα (HC-20), anti-AHR (H-211), anti-ARNT (C-19), or anti-CYP1B1 (H-105) overnight at 4°C with constant rocking. Membranes were washed 3 times with PBS/0.1% Tween 20 and incubated with an anti-rabbit secondary antibody for 1 h. For detection of β-actin, a primary mouse anti-β-actin antibody (Sigma) was incubated for 2 h at room temperature followed by 1-h incubation with anti-mouse horseradish peroxidase-conjugated secondary antibody. After washing, the proteins were visualized using ECL-Advance.
AHR and ARNT transfection experiments. MCF7 AHR ko
and MDA-MB-231 AHR ko cells were transfected with 500 ng of pRC-CMV2, 250 or 500 ng of pRC-AHR (Celius and Matthews, 2010) , or pRC-AHR DBDinsGS using Lipofectamine LTX (Invitrogen). The pRC-AHR DBDinsGS plasmid was generated by introducing a BamHI (GGATCC) site using PCR mutagenesis and the following primers: 5′-TCAAATCCTTCCAAGCG GCATAGAGGGATCCACCGACT TAATACAGAGTTGGACC-3′ and 5′-GG TCCAACTCTGTATTAA GTCGGTGGATCCCTC TATGCCGCT TGGAAGG ATTTGA-3′. The insertion of the BamHI site produced an in-frame insertion of a glycine and serine residue between arginine 40 and aspartic acid 41 of the DNA-binding domain. A similar mutagenesis strategy was used to disrupt the DNA-binding activity of murine AHR (Bunger et al., 2008) . MCF7 ARNT ko cells were transfected with 500 ng of pcDNA and 250 or 500 ng pcDNA4-ARNT (Partch and Gardner, 2011) using Lipofectamine LTX. Twenty-four hours after transfection, cells were treated with DMSO or 10nM TCDD for 24 h prior to RNA extraction. To examine the role of ARNT in ERα signaling, 2 μg of pcDNA or pcDNA4-ARNT were transfected into MCF7 ARNT ko cells using Lipofectamine LTX. Forty-eight hours after transfection, cells were treated with DMSO, TCDD, E2, or E2 + TCDD for 6 h before RNA was isolated and reverse transcribed as described above.
Statistical analysis.
All results were expressed as mean ± SEM. Statistically significant differences were determined using GraphPad Prism 5 statistical software (San Diego, California). One-way ANOVA followed by Tukey's multiple comparison tests and the Student's 2-tailed t tests were used when appropriate. Statistical significance was assessed at p < .05.
REsulTs

ZFN-Mediated AHR and ARNT Knockout in Human Breast
Cancer Cells
Our laboratory, like many others, has reported a marked reduction in AHR protein levels following RNAi-mediated knockdown; however, TCDD-dependent induction of CYP1A1 and CYP1B1 mRNA levels, albeit at reduced levels, were still observed (Abdelrahim et al., 2006; Ahmed et al., 2009) . The low level of residual protein expression may mask important cellular and regulatory roles of AHR. Gene knockout, rather than knockdown, is well recognized as the most powerful approach for determining gene function. With this in mind, we used ZFNs to knockout AHR or ARNT in ERα-positive (MCF7) and AHR in ERα-negative (MDA-MB-231) human breast cancer cells. We chose MCF7 cells because they express a functional AHR, ARNT, and ERα and are widely used to study AHR and ERα signaling. AHR is an established negative regulator of ERα, whereas ARNT has recently been reported to act as a potent coactivator of ERα transactivation (Brunnberg et al., 2003; Labrecque et al., 2012) , making MCF7 cells a good model to study AHR/ERα cross talk. We created MDA-MB-231 AHR ko cells because AHR has been proposed as an alternative therapeutic target for triple negative breast cancer (Zhang et al., 2009) .
The ZFN heterodimers targeting AHR or ARNT bound to genomic sequences downstream of the translational start codon within exon 1 of AHR on chromosome 7 and exon 14 of ARNT on chromosome 1, respectively. The activity of each ZFN pair was validated by Cel-1 assays (data not shown). Binding of the ZFN proteins created double-strand DNA breaks that resulted in out-of-frame deletions or insertions in both genes, and the resulting mutations in isolated cell clones were verified by DNA sequencing. The AHR ko cell lines identified after screening for AHR protein expression contained deletions of 4 and 20 nucleotides for MCF7 and 2 and 11 nucleotides for MDA-MB-231 cell clones causing the formation of a premature stop codon (Fig. 1A) . The MCF7 ARNT ko clone identified after screening for ARNT protein expression contained a deletion of 2 nucleotides or an insertion of 4 nucleotides resulting in the formation of a premature stop codon (Fig. 1B) .
Because altered expression of genes in tandem with the gene targeted by ZFN may occur, we determined the expression of genes directly upstream and downstream of AHR and ARNT. Targeted deletion of AHR in MCF7 cells did not affect the expression of SNX13 and AGR3 genes, which are located directly upstream and downstream of AHR, respectively. However, SNX13 mRNA levels were reduced in MDA-MB-231 AHR ko cells, and this could not be restored with transfection of AHR (Fig. 1C) . The reduced expression of SNX13 may be due to the introduced ZFN mutation at the AHR locus or could have arisen during the selection process. Deletion of ARNT in MCF7 cells did not affect the expression of SETDB1, the gene directly upstream of ARNT. However, the reduced mRNA expression level of CTSK, the gene directly downstream of ARNT, was restored with ectopic expression of ARNT (Fig. 1D ). To identify other sequences in the genome that might be targeted by the ZFN sequences, we preformed a computational sequence search using the ZFN-site web-based interface (Cradick et al., 2011) . Despite allowing for up to 2 mismatched bases and flexible spacing, no additional or potential off-target binding sites were identified in the human genome (hg18 and hg19) for either ZFN-binding pair.
Western blotting confirmed that ARNT protein levels were unchanged in the MCF7 AHR ko and MDA-MB-231 AHR ko cells compared with WT cells (Fig. 1E ). Because AHR regulates ERα protein expression, we determined ERα protein levels in AHR ko and ARNT ko cells (Abdelrahim et al., 2006) . Loss of AHR or ARNT, however, did not affect basal ERα protein levels in MCF7 AHR ko cells (Fig. 1E ). As expected, no ERα protein expression was observed in the MDA-MB-231 or MDA-MB-231 AHR ko cell lines (Fig. 1E ). Knockout of AHR or ARNT in the MCF7 cells caused a marked decrease in basal and prevented the TCDD-dependent induction of CYP1A1 and CYP1B1 mRNA levels ( Figs. 2A  and 2B ). The fold reduction in basal CYP1B1 mRNA levels (approximately 10 000-fold lower) was greater than that observed for CYP1A1 (approximately 10-fold lower). Similar findings were observed in MDA-MB-231 AHR ko cells (Figs. 2C and 2D). Although no longer responsive to TCDD, the basal mRNA levels of other known AHR target genes, including TCDD-inducible poly(ADP)-ribose polymerase (TiPARP, also known as ADP-ribosyltransferase diphtheria-like toxin 14) and nuclear factor (erythroid-derived 2)-like 2 (NFE2L2; NRF2), were unaffected by the loss of AHR or ARNT (Figs. 2E-H). TCDD-dependent induction of NFE2L2 mRNA was not observed in MDA-MB-231 cells.
AHR Knockout Does Not Affect Hypoxia-Inducible Factor 1α Signaling
ARNT is a general heterodimerization partner for other bHLH-PAS proteins, including hypoxia-inducible factor 1α (HIF-1α), which mediates the cellular response to hypoxia (Gu et al., 2000) . To ensure that AHR knockout did not alter HIF-1α/ARNT signaling and that this pathway was abolished in ARNT ko cells, we exposed MCF7, MCF7 AHR ko , MCF7 ARNT ko , MDA-MB-231, and MDA-MB-231 AHR ko cells to CoCl 2 for 24 h and determined the mRNA expression levels of VEGF and CA9, 2 hypoxia responsive genes. Exposure to CoCl 2 promotes a response similar to hypoxia. CoCl 2 -dependent increases in VEGF and CA9 mRNA levels were unaffected by AHR knockout in both MCF7 and MDA-MB-231 cells but were abolished in the MCF7 ARNT ko cells (Figs. 3A-D) , demonstrating that AHR-independent activities of ARNT were maintained in the MCF7 and MDA-MB-231 AHR ko cells.
Basal and Ligand-Induced CYP1B1 Levels Are Dependent on AHR and ARNT Expression
To determine if the reduced basal CYP1B1 mRNA levels correlated with AHR expression levels, we compared the CYP1B1 mRNA levels after RNAi-mediated knockdown of AHR or CYP1B1 with AHR or ARNT null cell lines. AHR knockdown resulted in small, but significant, decrease in CYP1B1 mRNA levels in MCF7 cells (Fig. 4A) . Similar results were observed in T-47D breast cancer cells expressing a doxycycline-inducible shRNA targeting AHR (data not shown). RNAi targeting CYP1B1 caused approximately a 63% reduction in CYP1B1 mRNA levels and a reduction in basal and TCDD-induced CYP1B1 protein levels (Figs. 4A and 4B) . However, AHR knockout in MCF7 and MDA-MB-231 cells reduced basal CYP1B1 mRNA and protein levels to a far greater extent than that achieved by CYP1B1 knockdown (Figs. 4A-C) . Similar findings were observed in MCF7 ARNT ko cells (Fig. 4B) . We next examined if the loss of basal CYP1B1 expression could be restored with ectopic expression of AHR or ARNT in the AHR ko or ARNT ko cell lines, respectively. As expected, increasing amounts of AHR or AHR DBDinsGS , an AHR insertion mutant that does not bind to AHREs (Bunger et al., 2008) , resulted in a concentration-dependent increase in AHR mRNA (data not shown). Transient overexpression of AHR, but not AHR DBDinsGS , restored the basal and TCDD-inducible CYP1B1 mRNA levels (Figs. 4D and 4E) , demonstrating that the AHR regulation of basal CYP1B1 mRNA levels required an intact DNA-binding domain. In agreement with the above findings, transfection of increasing amounts of ARNT into MCF7 ARNT ko cells restored the basal and TCDD-inducible CYP1B1 mRNA levels (Fig. 4F) .
ERα-Dependent Regulation of CYP1B1 Requires AHR
CYP1B1 is also regulated by E2 through ERα (Tsuchiya et al., 2004) ; however, it is not known if the loss of AHR or ARNT would influence the ability of ERα to regulate CYP1B1 expression. We previously reported that TCDD-bound AHR induced the recruitment of ERα to CYP1B1, suggesting that AHR plays a key role in modulating the ability of ERα to regulate this gene (Ahmed et al., 2009; Matthews et al., 2005) . ARNT has also been shown to act as a potent coactivator of ERα transactivation, suggesting that the loss of ARNT may influence the ability of ERα to regulate CYP1B1 (Brunnberg et al., 2003) . To this end, we used ChIP assays to determine the ligand-dependent recruitment of AHR, ARNT, ERα, nuclear receptor coactivator 3 (NCoA3/AIB1/RAC3/SRC3), and RNA pol II to a distal region (−900 bp) and proximal region (−250 bp) of CYP1B1 in AHR ko and ARNT ko cells. The distal region contains 4 AHREs and has been previously used to study AHR-dependent regulation of CYP1B1 (Matthews et al., 2005) , whereas the proximal region (−250 bp) contains an AHRE and a half-site ERE shown to be important for the E2-dependent regulation of CYP1B1 (Tsuchiya et al., 2004) . We have recently reported that AHR/ ARNT interact with both the distal and proximal regions to of CTSK and SETDB1, the genes directly upstream and downstream of ARNT, respectively. MCF7 and MCF7 ARNT null cells were transiently transfected with vector control (pcDNA) or pcDNA4-ARNT, and changes in mRNA levels were determined by qPCR. Gene expression levels significantly different (p < .05) compared with WT untransfected cells were denoted with an asterisk. E, Western blot analysis of AHR, ERα, and ARNT protein levels in MCF7, MCF7 AHR ko cells were treated with DMSO or 10nM TCDD, and the mRNA expression levels of CYP1A1 (A and C), CYP1B1 (B and D), TiPARP (E and G), and NFE2L2 (F and H) were determined as described in the Materials and Methods section. Data were normalized to ribosomal 18s levels and were shown relative to WT DMSO for the respective cell lines. All data were presented as means ± SEM for 3 independent experiments. Gene expression levels significantly different (p < .05) compared with WT DMSO-treated or WT TCDD-treated cells were denoted with an asterisk or a pound sign, respectively. Abbreviations: AHR, aryl hydrocarbon receptor; ARNT, AHR nuclear translocator; CYP1A1, cytochrome P4501A1; CYP1B1, cytochrome P4501B1; DMSO, dimethyl sulfoxide; NFE2L2, nuclear factor (erythroid-derived 2)-like 2; TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin; TiPARP, TCDD-inducible poly(ADP)-ribose polymerase; WT, wild-type.
regulate CYP1B1 (Macpherson and Matthews, 2010) . TCDD induced the recruitment of AHR, ARNT, Erα, and NCoA3 to the CYP1B1 distal region in MCF7 WT cells (Figs. 5A, 5C , 5E, and 5G). E2 alone did not significantly induce the recruitment of AHR, ARNT, or NCoA3 to the CYP1B1 distal region above solvent controls; however, a small but significant increase in ERα occupancy was observed (Figs. 5A, 5C , 5E, and 5G). Cotreatment of TCDD + E2 did not affect the recruitment levels of AHR or ARNT at the CYP1B1 distal region but increased the recruitment of ERα and NCoA3 (Figs. 5E and 5G). Treatment with TCDD or E2 alone increased the occupancy of AHR and ARNT at the CYP1B1 proximal region, which was significantly increased with TCDD + E2 cotreatment in the MCF7 WT cells (Figs. 5B and 5D ). The basal binding of ERα to the CYP1B1 proximal region was unaffected by TCDD but increased with exposure to E2 and further increased with TCDD + E2 cotreatment (Fig. 5F ). The recruitment profile of NCoA3 paralleled that of ERα at both regions (Figs. 5G and 5H ). The basal binding of RNA pol II to the distal region was unaffected by ligand, whereas its recruitment to the CYP1B1 proximal region was increased with TCDD, E2, or TCDD + E2 exposure (Figs. 5I-K). No ligand-dependent recruitment of AHR, ARNT, ERα, NCoA3, or RNA pol II to the distal or proximal regions of CYP1B1 or changes in CYP1B1 mRNA levels were observed in MCF7 AHR ko cells (Figs. 5A-K). However, loss of ARNT resulted in increased basal binding of AHR at the distal region and E2-and TCDD + E2-dependent increases at the proximal region (Figs. 5A and 5B). E2-dependent recruitment of ERα, NCoA3, and RNA pol II to the proximal region was maintained, albeit at reduced levels, in the MCF7 ARNT ko compared with WT cells.
Despite the increased recruitment of AHR, ARNT, and NCoA3 to the CYP1B1 proximal region after TCDD + E2 cotreatment, no increase in CYP1B1 mRNA expression levels compared with TCDD alone was observed in WT cells (Fig. 5K) . A small, but significant, E2-dependent increase in CYP1B1 mRNA levels was also observed. Although the CYP1B1 mRNA levels were greatly reduced in MCF7 ARNT ko cells, a small E2-dependent increase that was unaffected by TCDD + E2 cotreatment was observed (Fig. 5K) . These results revealed that the loss of AHR or ARNT prevented basal and TCDD-dependent regulation of CYP1B1 by abolishing the recruitment of NCoA3 and RNA pol II to CYP1B1. The E2-dependent regulation of CYP1B1 was negatively affected by the loss of both AHR and ARNT, but the loss of AHR abolished this regulation, whereas small but significant increases were determined by qPCR as described in Materials and Methods section. Data were normalized to ribosomal 18s levels and were shown relative to WT DMSO for the respective cell lines. All data were presented as means ± SEM for 3 independent experiments. Gene expression levels significantly different (p < .05) compared with WT DMSO-treated or WT CoCl 2 -treated cells were denoted with an asterisk or a pound sign, respectively. Abbreviations: AHR, aryl hydrocarbon receptor; ARNT, AHR nuclear translocator; CA9, carbonic anhydrase IX; DMSO, dimethyl sulfoxide; VEGF, vascular endothelial growth factor; WT, wild-type.
in mRNA and ERα recruitment to CYP1B1 were observed in ARNT ko cells.
ERα Enhances the AHR-Dependent Regulation of CYP1B1 in MDA-ERα Cells
To confirm the importance of AHR in the basal and liganddependent regulation of CYP1B1 in another cell line and to determine the impact of ERα expression on this regulation, we performed ChIP and mRNA expression analyses in the MDA-MB-231, MDA-MB-231 AHR ko , and MDA-ERα cells. TCDD and E2 + TCDD as well as ERα status did not affect AHR or ARNT recruitment to the CYP1B1 distal region (Figs. 6A and  6C ). As expected, TCDD-, E2-, and TCDD + E2-dependent recruitment of ERα to the CYP1B1 distal region was only observed in MDA-ERα (Fig. 6E) . NCoA3 exhibited a similar recruitment profile to the distal region in MDA-ERα as in WT cells, but at reduced levels (Fig. 6G) . No E2-dependent recruitment of AHR, ARNT, or NCoA3 was observed to the distal region. RNA pol II binding was unaffected by ligand treatment or receptor status (AHR or ERα) at the CYP1B1 distal region (Fig. 6I) . In MDA-MB-231 WT cells, we observed basal but not ligand-induced occupancy of AHR and ARNT at CYP1B1 proximal region. No recruitment of AHR, ARNT, ERα, NCoA3, or RNA pol II was observed in AHR ko cells (Figs. 6A-J) . Similar to that observed at the distal region, E2 and TCDD + E2, but not TCDD, induced the recruitment of ERα to the CYP1B1 proximal region in MDA-ERα cells (Fig. 6F) . Interestingly, stable expression of ERα resulted in increased TCDD + E2-dependent recruitment of AHR and ARNT to the CYP1B1 proximal region compared with TCDD alone (Figs. 6B and 6D ).
FIG. 4.
Basal and ligand-induced CYP1B1 levels were dependent on AHR and ARNT expression. A, CYP1B1 mRNA levels were determined by qPCR after RNAi-mediated AHR or CYP1B1 knockdown, or in AHR or ARNT knockout cells. The percent reduction in CYP1B1 mRNA levels compared with their respective nontargeting siRNA control cells or MCF-7 WT cells, which were set to 100%, were provided in the graph. B, CYP1B1 protein levels in MCF7 (WT), MCF7 cells after RNAi-mediated CYP1B1 knockdown, or in AHR ko and ARNT ko MCF7 cells following 24-h treatment with DMSO (D) or TCDD (T). The data shown were representative of 3 independent experiments. Protein levels were quantified using ImageJ (NIH). Asterisks denoted statistically significant changes compared with DMSO-treated MCF7, whereas pound sign denoted statistically significant changes compared with TCDD-treated MCF7 cells (p < .05). C, CYP1B1 protein levels in MDA-MB-231 (WT), MDA-MB-231 cells after transfection with a nontargeting pool siRNA or siRNA targeting CYP1B1, or in MDA-MB-231 AHR ko cells following 24-h treatment with DMSO (D) or TCDD (T). The data shown were representative of 3 independent experiments. Protein levels were quantified using ImageJ (NIH). Asterisks denoted statistically significant changes compared with DMSO-treated MCF7, whereas pound sign denoted statistically significant changes compared with TCDD-treated MCF7 cells (p < .05). D and E, AHR or (F) ARNT restores CYP1B1 mRNA levels in AHR ko and ARNT ko cells, respectively. MCF7 AHR ko (D) or MDA-MB-231 AHR ko cells (E) were transiently transfected with vector pRC, increasing amounts of pRC-AHR or pRC-AHR DBDinsGS . AHR protein levels and CYP1B1 transcript levels were determined as described in Materials and Methods section. MCF7 ARNT ko cells (F) were transiently transfected with vector pcDNA or increasing amounts of pcDNA4-ARNT (ARNT) . ARNT protein levels and CYP1B1 transcript levels were determined as described in Materials and Methods section. All data were presented as means ± SEM for 3 independent experiments. Gene expression levels significantly different (p < .05) compared with treatment-matched empty vector transfected cells or treatment-matched transfected cells were denoted with an asterisk or a pound sign, respectively. Abbreviations: AHR, aryl hydrocarbon receptor; ARNT, AHR nuclear translocator; CYP1B1, cytochrome P4501B1; DMSO, dimethyl sulfoxide; NIH, National Institutes of Health; TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin. , and MCF7 ARNT ko were treated with DMSO, 10nM TCDD, 10nM E2, or E2 + TCDD for 45 min, and the recruitment of AHR (A and B), ARNT (C and D), ERα (E and F), NCoA3 (G and H), and RNA pol II (I and J) to the distal and proximal regions of CYP1B1 was determined using ChIP assays. All data were relative to 100% total input and represent the means ± SEM from 3 independent experiments. Enrichment levels significantly greater (p < .05) compared with cell line-matched DMSO or with WT IgG DMSO were denoted with an asterisk or pound sign, respectively. K, Analysis of CYP1B1 mRNA levels in MCF7 (WT), MCF7 AHR ko , and MCF7 ARNT ko cells using qPCR. All data were normalized to 18s levels and were compared relative to WT DMSO-treated cells. Gene expression levels significantly different (p < .05) compared with cell line-matched DMSO-treated cells were denoted with an asterisk. Abbreviations: AHR, aryl hydrocarbon receptor; ARNT, AHR nuclear translocator; ChIP, chromatin immunoprecipitation; CYP1B1, cytochrome P4501B1; DMSO, dimethyl sulfoxide; ERα estrogen receptor α; TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin. , and MDA-MB-231 cells stably expressing ERα (MDA-ERα) were treated with DMSO, 10nM TCDD, 10nM E2 or E2 + TCDD for 45 min, and the recruitment of AHR (A and B), ARNT (C and D), and ERα (E and F), NCoA3 (G and H), and RNA pol II (I and J) to the distal and proximal regions of CYP1B1 was determined using ChIP assays. All data were relative to 100% total input and represent the means ± SEM from 3 independent experiments. Enrichment levels significantly greater (p < .05) than cell line-matched DMSO or WT IgG DMSO were denoted with an asterisk or pound sign, respectively. K, CYP1B1 mRNA levels in MDA-MB-231 (WT), MDA-MB-231 AHR ko , and MDA-ERα cells after 6-h treatment with the indicated ligands as described in Materials and Methods section. Gene expression levels significantly different (p < .05) compared with cell line-matched DMSO samples or treatment-matched WT cells were denoted with an asterisk or a pound sign, respectively. Abbreviations: AHR, aryl hydrocarbon receptor; ARNT, AHR nuclear translocator; ChIP, chromatin immunoprecipitation; CYP1B1, cytochrome P4501B1; DMSO, dimethyl sulfoxide; ERα estrogen receptor α; TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin. E2-and E2 + TCDD-dependent recruitment of NCoA3, which was not observed in WT cells, was also observed (Fig. 6H) . RNA pol II was recruited in a TCDD-dependent manner in the MDA-MB-231 cells; however, occupancy levels did not increase above DMSO in MDA-ERα cells (Fig. 6J) . The expression of ERα resulted in a weak, but significant, E2-dependent increase in CYP1B1 mRNA levels. Increased TCDD-induced CYP1B1 mRNA levels were observed in MDA-ERα compared with WT cells (Fig. 6K) . No ligand-dependent increases in CYP1B1 mRNA levels were observed in the MDA-MB-231 AHR ko cells. These data demonstrated that although ERα is not required for AHR regulation of CYP1B1, its expression modulates the recruitment of AHR and ARNT to the CYP1B1 proximal region and it can positively influence the ability of AHR/ ARNT to regulate CYP1B1 expression.
Loss of AHR and ARNT Differentially Affects ERα Transactivation
Ligand-activated AHR inhibits ERα signaling through a number of proposed mechanisms, including direct inhibition at the gene level and through increased proteolytic degradation (Matthews et al., 2006) . ARNT has recently been reported to act as a potent coactivator of ERα transactivation, suggesting that AHR modulates estrogen responses by reducing the pool of ARNT available to coactivate ERα transactivation (Brunnberg et al., 2003; Labrecque et al., 2012) . To determine the impact of AHR and ARNT knockout on ERα signaling, we examined the TCDD-and E2-dependent regulation of 2 estrogen target genes, TFF-1 and GREB1, in MCF7, MCF7 AHR ko , and MCF7 ARNT ko cells. AHR and ARNT were recruited to the regulatory region of TFF-1 after TCDD, E2, and E2 + TCDD treatment in MCF7 WT cells (Figs. 7A and 7B) . Loss of AHR prevented the ligand-dependent increases in AHR and ARNT recruitment to both genes, although increased basal binding of ARNT was observed (Fig. 7B) . Similar findings were observed in MCF-7 ARNT ko cells except that increased basal binding of AHR was observed (Figs. 7A and 7D ). ERα recruitment to both genes was increased with E2 and E2 + TCDD but not TCDD alone in MCF7 WT cells (Figs. 7C and 7F ). Greater ERα occupancy compared with MCF7 WT cells was observed at TFF-1 in MCF7 AHR ko but not in MCF7 ARNT ko cells. TCDD + E2 cotreatment did not alter E2-dependent recruitment of ERα to either gene. AHR and ARNT knockout prevented the TCDD-dependent inhibition of E2-induced TFF-1 expression levels (Fig. 7G) . Increases in E2-dependent TFF-1 and GREB1 mRNA expression levels were observed in MCF7 AHR ko (Figs. 7G and 7I) . Reduced basal expression of TFF-1, but not GREB1, was observed in the MCF7 ARNT ko cells, which was restored with ectopic expression of ARNT (Fig. 7H) . We next determined the ability of AHR and ARNT to influence the ligand-induced degradation of ERα. In MCF7 cells, E2 treatment for 24 h reduced ERα protein levels, which were further reduced with TCDD + E2 cotreatment. TCDD failed to enhance the E2-dependent degradation of ERα protein levels in MCF7 AHR ko and MCF7 ARNT ko cells (Fig. 7J ), confirming the importance of both AHR and ARNT in regulating the TCDD-dependent decreases in ERα protein levels.
DIsCussION
In this study, we used targeted ZFN-mediated knockout of AHR and ARNT in human breast cancer cells to dissect the AHR signaling pathway and to characterize the mechanisms of cross talk among AHR, ARNT, and ERα. Our data show that the AHR/ARNT heterodimer is absolutely required for the TCDDinduced and basal expression of CYP1B1. We also report that AHR, but not ARNT, is required for ERα-dependent increases in CYP1B1 levels. Both AHR and ARNT are required for TCDD-dependent increases in ERα proteolytic degradation but differentially affect ERα transactivation. This study increases our understanding of AHR signaling and its impact on ERα transactivation but also describes new cell models to delineate the complex interplay between both receptor pathways.
ZFN, TALEN, and CRISPR approaches are emerging technologies that permit the targeted gene knockout in immortalized cells and nonmurine animal models (Cong et al., 2013; DeFrancesco, 2011; Porteus and Carroll, 2005) , offering new possibilities to study AHR signaling. Recently, AHR −/− Sprague Dawley rats harboring deletion mutations in exon 2 of the AHR were created using ZFN methodology (Harrill et al., 2013) . Similar to AHR −/− mice, AHR −/− rats are insensitive to TCDD-induced toxicity and the induction of AHR-responsive genes. However, AHR −/− rats displayed pathological alterations in the urinary tract, whereas compromised hepatic function and alterations in the patent ductus venosus were only observed in AHR −/− mice (Harrill et al., 2013) . These findings illustrate the utility of the ZFN approach and show that AHR exhibits distinct roles in development, tissue homeostasis, and toxicity across rodent species.
One of the most interesting findings from our study was the large reduction in basal CYP1B1 and CYP1A1 transcript levels in the AHR ko and ARNT ko cells. The reduction in CYP1B1 expression levels requires the AHR/ARNT heterodimer and a functional AHR DNA-binding domain. These data support the idea that therapeutic targeting of AHR protein levels may be an alternative approach to target CYP1B1 in human disease. Although some of the basal AHR and ARNT binding to and expression of CYP1B1 may be due to tryptophan photooxidation products including 6-formylindolo[3,2-b]carbazole or other potential activators of AHR present in the cell culture media, reductions in basal expression of TiPARP or NFE2L2 was not observed, suggesting that this aspect of AHR action exhibits promoter specificity. The importance of AHR expression levels in the regulation of CYP1B1 is supported by RNAi studies targeting AHR, AH R100 cells, and mouse embryonic fibroblasts isolated from AHR −/− mice as well as liver tissue from AHR −/− Sprague Dawley rats (Harrill et al., 2013; Spink et al., 2012; Zhang et al., 1998 , and MCF7 ARNT ko were treated with DMSO, 10nM TCDD, 10nM E2 or E2 + TCDD for 45 min. AHR (A and D), ARNT (B and E), and ERα (C and F) recruitment to TFF-1 and GREB1 was determined using ChIP assays. All data were relative to 100% total input and represent the means ± SEM from 3 independent experiments. Enrichment levels significantly greater (p < .05) than cell line-matched DMSO or WT IgG DMSO were denoted with an asterisk or pound sign, respectively. The dagger represents significantly greater increases in enrichment compared with treatment-matched WT cells. (G and I) TFF-1 and GREB1 mRNA levels in MCF7 (WT), MCF7 AHR ko , and MCF7 ARNT ko cells after 6-h treatment with the indicated ligands as described in Materials and Methods section. Gene expression levels significantly different (p < .05) compared with cell line-matched DMSO samples or treatment-matched WT cells were denoted with an asterisk or a pound sign, respectively. H, Overexpression of ARNT in MCF7 ARNT ko restored E2-dependent induction of TFF-1. MCF7 cells were transfected as described in the Materials and Methods section. J, ERα protein levels after 24-h exposure of WT, AHR, and ARNT knockout cells to DMSO (D), TCDD (T), E2, or E2 + TCDD (E/T). β-Actin was used to control as a loading control. Abbreviations: AHR, aryl hydrocarbon receptor; ARNT, AHR nuclear translocator; ChIP, chromatin immunoprecipitation; DMSO, dimethyl sulfoxide; ERα estrogen receptor α; GREB1, growth regulation by estrogen in breast cancer 1; TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin, TFF-1, trefoil factor 1. differences in basal CYP1B1 mRNA levels were reported in liver extracts isolated from WT compared with Ahr −/− mice (Hushka et al., 1998; Tijet et al., 2006) . This may be due to its regulation by other signaling molecules such as SF-1, CREB, and cAMP (Zhang et al., 2003; Zheng and Jefcoate, 2005 ) that do not occur in the AHR null cell lines described here or other transcription factors that do not occur in the immortalized AHR null human cancer cell lines described here. However, cAMP induces the nuclear translocation of AHR, suggesting that the cAMP-dependent regulation of CYP1B1 requires a functional AHR and that this regulation would also be affected in AHR ko cells (Oesch-Bartlomowicz et al., 2005) ERα has been reported to direct the release of paused RNA pol II at the CYP1B1 promoter (Kininis et al., 2007) , and ERα-dependent regulation of CYP1B1 expression is thought to increase breast cancer risk (Tsuchiya et al., 2004) . Consistent with these data, we observe basal binding of RNA pol II at the CYP1B1 proximal region in MCF7 cells, which was increased following E2 treatment resulting in weak estrogen-dependent increases in CYP1B1 mRNA levels. Loss of AHR, but not ARNT, completely abolishes ERα-dependent regulation of and ERα recruitment to CYP1B1. It is, however, unclear whether the small but significant E2-dependent increases in CYP1B1 mRNA levels and recruitment of ERα to CYP1B1 that we observe in MCF7 ARNT ko cells result in physiologically significant changes in CYP1B1 protein levels or enzymatic activity. Moreover, some of the differences in estrogen-dependent regulation of CYP1B1 in the MCF7 AHR ko and ARNT ko cells may be due to changes in the stoichiometric relationships among AHR, ARNT, and ERα that would be greatly altered compared with those observed under natural conditions. Nonetheless, our data reveal that AHR is required for estrogen-dependent regulation of CYP1B1 expression in human breast cancer cells by facilitating the binding of NCoA3 and RNA pol II during ERα-dependent regulation of CYP1B1. The increase in TCDD-induced CYP1B1 mRNA levels in MDA-ERα cells is in agreement with the notion that when coexpressed, AHR and ERα work together to regulate CYP1B1. The AHR-dependent regulation observed in the parent ERα-negative MDA-MB-231 cells may be due to the reported low levels of ERβ in these cells (Vladusic et al., 2000) or may reflect that AHR can also regulate CYP1B1 independently of ERs. The increased recruitment of AHR, ARNT, NCoA3, and ERα to CYP1B1 supports the observed increases in CYP1B1 mRNA levels following treatment with TCDD or TCDD + E2. The lack of NCoA3 and ERα recruitment to the proximal CYP1B1 region after TCDD is unclear because both proteins are recruited to this region after E2 or TCDD + E2 cotreatment. It is possible that another coregulator or accessory protein that was not tested in the current study is recruited to this region in a TCDD-dependent manner, whereas the NCoA3 binding to the proximal region is dependent on ERα and E2 rather than TCDD.
AHR or ARNT knockout prevented the TCDD-dependent inhibition of ERα transactivation and the proteolytic degradation of ERα. This latter finding reveals that the ability of AHR to influence ERα protein levels requires ARNT and vice versa. At the gene level, AHR knockout enhances ERα transactivation in a promoter selective manner with increased basal and E2-dependent upregulation of TFF-1 compared with GREB1. These differences may be due to lack of AHR binding at an inhibitory AHRE sequence at TFF-1 . Although ARNT has been reported to act as an ERα coactivator (Brunnberg et al., 2003; Labrecque et al., 2012) , TCDD-, E2-, or TCDD + E2-induced recruitment of both ARNT and AHR was only observed in WT cells. Loss of ARNT increased the basal binding of AHR to TFF-1 and GREB1 and vice versa, but neither AHR nor ARNT was recruited to TFF-1 or GREB1 in a ligand-dependent manner in the absence of the other, suggesting that both are important modulators of ERα action. However, ARNT knockout does not alter ERα recruitment to TFF-1 but prevents E2-dependent induction of TFF-1 mRNA levels. This is consistent with ARNT knockdown studies in MCF7 cells, which show reduced E2-dependent TFF-1 expression when compared with control cells (Labrecque et al., 2012) . Taken together, our data support a role of ARNT in ERα transactivation, but it also remains possible that the small increases in AHR occupancy at TFF-1 evident in the absence of ARNT are responsible for the inhibition of TFF-1 expression. The finding that a functional AHR/ARNT heterodimer is required for inhibition of ERα signaling is supported by the fact that TCDDdependent inhibition of TFF-1 is lost in both AHR ko and ARNT ko cells. This is in contrast to RNAi-mediated AHR and ARNT knockdown studies in MCF7 cells, which showed that after the ARNT knockdown, AHR still inhibited E2 transactivation (Labrecque et al., 2012) . However, as mentioned above, residual ARNT protein expression that remains after knockdown could have been sufficient to contribute to the reported inhibition of ERα transactivation. Overall, our findings reveal new insight into AHR/ARNT mechanism of action and how both proteins function together but also independently to modulate ERα in a context-dependent manner. The importance of AHR in regulating CYP1B1 expression may have important implications for breast cancer through the reduction of reactive estrogen metabolites generated by CYP1B1. The ZFN-mediated AHR ko and ARNT ko cell lines described here represent excellent tools to further delineate AHR/ARNT signaling in breast cancer cells. This approach can be used to create additional AHR ko and ARNT ko cell lines that could provide important cell-and context-dependent insight into pathways regulated by AHR. 
